<!--
title: Ivermectin has New Application in Inhibiting Colorectal Cancer Cell Growth
description: doi: 10.3389/fphar.2021.717529
published: true
date: 2022-02-11T13:10:32.106Z
tags: ivermectin, treatment, cancer, antiparasitic, cure, colorectal, cell, illness, growth
editor: ckeditor
dateCreated: 2022-02-11T13:10:32.106Z
-->

<p><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415024/#">Front Pharmacol.</a> 2021; 12: 717529.</p>
<p>Published online 2021 Aug 13. doi:&nbsp;<a href="https://dx.doi.org/10.3389%2Ffphar.2021.717529">10.3389/fphar.2021.717529</a></p>
<p style="text-align:right;">PMCID: PMC8415024</p>
<p style="text-align:right;">PMID: <a href="https://www.ncbi.nlm.nih.gov/pubmed/34483925">34483925</a></p>
<p>&nbsp;</p>
<h1>Ivermectin has New Application in Inhibiting Colorectal Cancer Cell Growth</h1>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Zhou%20S%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=34483925">Shican Zhou</a>,<sup> ‡ </sup><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Wu%20H%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=34483925">Hang Wu</a>,<sup> ‡ </sup><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Ning%20W%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=34483925">Wenjuan Ning</a>, <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Wu%20X%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=34483925">Xiao Wu</a>, <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Xu%20X%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=34483925">Xiaoxiao Xu</a>, <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Ma%20Y%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=34483925">Yuanqiao Ma</a>, <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Li%20X%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=34483925">Xingwang Li</a>, <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Hu%20J%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=34483925">Junhong Hu</a>,<sup>* † , § </sup><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Wang%20C%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=34483925">Chenyu Wang</a>,<sup> § </sup>and <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Wang%20J%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=34483925">Junpeng Wang</a><sup>* §</sup></p>
<p><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415024/#">Author information</a> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415024/#">Article notes</a> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415024/#">Copyright and License information</a> <a href="https://www.ncbi.nlm.nih.gov/pmc/about/disclaimer/">Disclaimer</a></p>
<h2>Associated Data</h2>
<p><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415024/#">Supplementary Materials</a></p>
<p><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415024/#">Data Availability Statement</a></p>
<p><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415024/#">Go to:</a></p>
<p style="text-align:right;">&nbsp;</p>
<h2>Abstract</h2>
<p>Colorectal cancer (CRC) is the third most common cancer worldwide and still lacks effective therapy. Ivermectin, an antiparasitic drug, has been shown to possess anti-inflammation, anti-virus, and antitumor properties. However, whether ivermectin affects CRC is still unclear. The objective of this study was to evaluate the influence of ivermectin on CRC using CRC cell lines SW480 and SW1116. We used CCK-8 assay to determine the cell viability, used an optical microscope to measure cell morphology, used Annexin V-FITC/7-AAD kit to determine cell apoptosis, used Caspase 3/7 Activity Apoptosis Assay Kit to evaluate Caspase 3/7 activity, used Western blot to determine apoptosis-associated protein expression, and used flow cytometry and fluorescence microscope to determine the reactive oxygen species (ROS) levels and cell cycle. The results demonstrated that ivermectin dose-dependently inhibited colorectal cancer SW480 and SW1116 cell growth, followed by promoting cell apoptosis and increasing Caspase-3/7 activity. Besides, ivermectin upregulated the expression of proapoptotic proteins Bax and cleaved PARP and downregulated antiapoptotic protein Bcl-2. Mechanism analysis showed that ivermectin promoted both total and mitochondrial ROS production in a dose-dependent manner, which could be eliminated by administering N-acetyl-l-cysteine (NAC) in CRC cells. Following NAC treatment, the inhibition of cell growth induced by ivermectin was reversed. Finally, ivermectin at low doses (2.5 and 5&nbsp;µM) induced CRC cell arrest. Overall, ivermectin suppressed cell proliferation by promoting ROS-mediated mitochondrial apoptosis pathway and inducing S phase arrest in CRC cells, suggesting that ivermectin might be a new potential anticancer drug therapy for human colorectal cancer and other cancers.</p>
<p><strong>Keywords: </strong>ivermectin, colorectal cancer, oxidative stress, apoptosis, cell cycle</p>
<p>&nbsp;</p>
<p>Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415024/</p>
